On 19 November 2018, orphan designation (EU/3/18/2100) was granted by the European Commission to Quality Regulatory Clinical Ireland Limited, Ireland, for propagermanium for the treatment of focal segmental glomerulosclerosis.
The sponsorship was transferred to Raremoon Consulting Esp S.L., Spain in June 2020.
|Disease / condition||
Treatment of focal segmental glomerulosclerosis
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.